Name: a bioluminescent and fluorescent orthotopic syngeneic murine model of androgen-dependent and castration-resistant prostate cancer
Uploaded: 2018-03-06T14:30:00.000+00:00
Duration: 7 min 25 s
Description: Watch this Scientific Journal Video about A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer at JoVE.com

This work was supported by National Institutes of Health grants to Praveen Thumbikat (NIDDK R01 DK094898), Sarki Abdulkadir (NCI R01 CA167966, NCI R01 CA123484, NCI P50 CA180995), and Jonathan Anker (NCI F30 CA203472).

All of the animal procedures outlined in this protocol are to be performed in compliance with ethical regulations and the approval of the appropriate university Institutional Animal Care and Use Committee (IACUC).
1. Preparation of Surgical Materials and Cancer Cells
<ol>
	<li>Before the day of surgery, autoclave the micro-dissecting scissors, Graefe forceps, Graefe tissue forceps, needle holder with suture cutters, and the appropriate number of drapes. Sterilize a 50 &#181;L syringe and 28-gauge needles by ethylene oxide gas (Figure 1C).</li>
	<li>Before the day of surgery, culture Myc-CaP cells in 10 cm dishes in RPMI supplemented with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin (P/S) in a 37 &#176;C 5% CO2 incubator. For bioluminescent and/or fluorescent tumor monitoring, transfect 293T cells with the appropriate vectors and subsequently transduce Myc-CaP cells with 0.45 &#181;m filtered lentivirus31. Sort cells to generate a stable cell line with 100% transduction positivity. 
	NOTE: Perform all tissue culture under sterile conditions, and verify that all cell lines are mycoplasma-free. The murine prostate cancer cell line utilized in this study, Myc-CaP32, is transduced to stably express both firefly luciferase and mCherry. The Myc-CaP cell line iss isolated from a c-myc-overexpressing Hi-myc mouse, and these cells contain an amplified androgen receptor (AR), which are androgen-dependent32 and form CRPC tumors after murine castration33. All mice in this study are 6-8 week old male FVB/NJ mice. Alternative murine prostate cancer cell lines can be used with the mice of appropriate genetic background, as well as human prostate cancer cell lines or primary patient-derived prostate cancer cells with immunodeficient mice. The optimal number of cells per injection should be determined empirically for alternative cell lines. In addition, alternative imaging modalities can be utilized to visualize tumors, including magnetic resonance imaging (MRI), positron emission tomography (PET), or computed tomography (CT), as well as GFP as an alternative to mCherry.</li>
	<li>The night before surgery, place matrigel basement membrane matrix and phenol red-free on ice at 4 &#176;C to thaw.</li>
	<li>On the day of surgery, collect the cells by washing them with phosphate buffered saline (PBS) and detaching with 0.25% trypsin-EDTA. Neutralize trypsin with RPMI with 10% FBS and 1% P/S.</li>
	<li>Centrifuge the cells at 400 x g for 5 min.</li>
	<li>Wash the cells with 10 mL of RPMI without FBS or P/S.</li>
	<li>Count the cells and resuspend the cells in PBS at a concentration of 6.67x107 cells/mL (1&#215;106 cells/15 &#181;L).</li>
	<li>Add an equal volume of matrigel to create a 1:1 PBS/matrigel cell suspension at a final concentration of 1&#215;106 cells/30 &#181;L, and keep the cells on ice until injection to prevent solidification. 
	NOTE: Perform intra-prostatic injections within 3 h of preparing matrigel cell suspensions. If performing intra-prostatic injections on more than 5 mice, repeat the above steps to prepare a fresh matrigel cell suspension.</li>
</ol>
2. Pre-operative mouse preparation
NOTE: House mice in the university animal facility for at least one week before surgery to allow for adequate adaptation and to minimize animal stress. Steps 2.1-2.6 are performed by the surgeon assistant. All subsequent surgical steps are performed by the surgeon using sterile gloves and surgical tools with sterile technique.
<ol>
	<li>Anesthetize the mice with isoflurane (2-5% for induction via chamber, 1-3% for maintenance via nose cone). Verify full induction by the loss of toe pinch reflex.</li>
	<li>Weigh the mice and administer at least 0.05 mg/kg of the analgesic buprenorphine s.c. 
	NOTE: Mouse weight &#8805;20 g is ideal for successful intra-prostatic injections.</li>
	<li>Apply ophthalmic ointment lubrication to both eyes to prevent corneal drying.</li>
	<li>Shave all fur from the abdomen.</li>
	<li>Sterilize the abdomen by three rounds of circular application of surgical scrub using sterile non-adhering pads followed by sterile alcohol wipes. Allow the abdomen to dry. 
	NOTE: For the rest of the surgical procedure, only sterile gloves and surgical instruments can contact the sterilized mouse abdomen.</li>
	<li>Transfer the mouse supine onto a clean surface on a heating pad directly under the objective of a clean surgical microscope.</li>
	<li>Cover the mouse with a sterile drape with a small hole cut over the abdomen.</li>
</ol>
3. Intra-prostatic injection
NOTE: Perform all surgical steps under sterile conditions. Adjusting the microscope, the mouse placement, or any other non-sterile objects must be done by the surgeon assistant.
<ol>
	<li>Perform an approximately 1 cm incision of the outer skin along the midline of the abdomen superior to the penis and the preputial glands (Figure 1D).</li>
	<li>Separate the connective tissue between the outer abdominal skin and the inner abdominal musculature by opening the scissors between the layers.</li>
	<li>Perform a similar incision of the inner abdominal musculature while using forceps to raise the musculature to avoid puncturing the intestines or bladder (Figure 1D).</li>
	<li>Locate one of the bilateral seminal vesicles (Figure 1A, white)/anterior prostate lobes (Figure 1A, black), which are often posterior, lateral, and slightly superior to the bladder (Figure 1A, yellow), but this may vary between mice. The anterior prostate lobes are translucent and attached to the lesser curvature of the white seminal vesicles.</li>
	<li>Gently raise the tip of the seminal vesicle using the Graefe tissue forceps to create tension on the tissue without puncturing the seminal vesicle (Figure 1E).</li>
	<li>Mix the Myc-CaP matrigel solution by gentile pipetting (performed by the surgeon assistant), as cells may have pelleted, and slowly aspirate 30 &#181;L (1x106 cells) into the needle to avoid air bubbles.</li>
	<li>Carefully insert the bevel of the needle parallel to the long axis of the anterior prostate lobe. Slowly inject 30 &#181;L into the lobe and slowly retract the needle to prevent leakage (Figure 1F). Verify adequate injection by engorgement of the anterior prostate lobe (Figure 1G).</li>
	<li>Carefully hold the seminal vesicle and injected prostate lobe outside of the mouse for approximately 30 s to allow matrigel to partially solidify within the lobe. During this time, collect any cell solution leakage in the abdomen using a sterile polyester tipped applicator to prevent non-orthotopic tumor development, without pressing on the injected prostate lobe.</li>
	<li>Carefully return the seminal vesicle and injected prostate lobe into the abdomen without putting pressure on the lobe. Replace any externalized tissues.</li>
	<li>Perform continuous sutures to close the inner abdominal musculature with 5-0 vicryl absorbable reverse cutting needle sutures.</li>
	<li>Perform interrupted sutures to close the outer abdominal skin with 4-0 nylon monofilament non-absorbable reverse cutting needle sutures. 
	NOTE: Sterilized 9 mm staples can also be used to close the outer abdominal skin. However, in contrast to sutures, they interfere with any subsequent bioluminescent and fluorescent tumor imaging signal.</li>
	<li>Clean all tools with sterile ethanol wipes (opened by the surgeon assistant) and place them in a glass bead sterilizer for 30 s. Allow the tools to dry before use on the next mouse.</li>
	<li>Flush the syringe and needle in sterile saline (opened by the surgeon assistant) to prevent clogging by remnant matrigel. 
	NOTE: A surgeon assistant should be present for all operations, performing all non-sterile pre-operative mouse preparation and post-operative mouse care, as well as to mix the Myc-CaP matrigel solution before injections. To minimize time, as each intra-prostatic mouse procedure will require 20-30 min, the surgeon assistant can begin preparing the next mouse as the surgeon is suturing the current mouse.</li>
</ol>
4. Post-operative Mouse Care
<ol>
	<li>Administer 1 mg/kg of the analgesic meloxicam s.c. immediately, 24 h, and 48 h after surgery.</li>
	<li>Allow mice to recover in a cage with no bedding placed halfway on a heating pad. Monitor mice for at least 30 min after surgery until they regain normal mobility and activity, after which place them in a clean cage with food on the floor of the cage.</li>
	<li>Further monitor mice daily for proper wound healing, body weight, grooming, and ambulation after surgery. Separate mice into individual cages upon any evidence of fighting.</li>
	<li>Remove any remaining sutures within 14 days after surgery.</li>
</ol>
5. Bioluminescent Tumor Imaging
<ol>
	<li>Prepare sterile-filtered Na+ or K+ D-luciferin, as described by the manufacturer and protected from light.</li>
	<li>Inject mice intra-peritoneally with 10 &#181;L/g of body weight of luciferin.</li>
	<li>At least 10 min later, image mice with an IVIS Spectrum Imaging System, as previously described34,35.</li>
	<li>Analyze images using Living Image Software, as previously described34,35. 
	NOTE: IVIS imaging analysis is useful for determining successful intra-prostatic injections and initial tumor development to normalize tumor burden among experimental groups. However, depending on the intensity of the bioluminescent or fluorescent signal, saturation may cause a plateau in the image quantification despite an increase in actual tumor size. Therefore, in the later stages of tumor growth, IVIS imaging may be more useful to determine decreases in tumor size upon successful treatment rather than increases in size after image saturation.</li>
</ol>
6. Tumor Collection, Tumor Analysis, Survival Endpoint
<ol>
	<li>If collecting tumor for analysis, humanely euthanize mice by CO2 exposure and secondary cervical dislocation, or by alternative IACUC approved methods, and dissect tumors from the abdomen. Tumors should be located orthotopically at the prostate. 
	NOTE: Tumors attached to the anterior abdominal wall or seeded throughout the abdomen indicate poor or leaky intra-prostatic injection, and should not be considered orthotopic tumors.</li>
	<li>Weigh the tumors.</li>
	<li>Calculate tumor volume as &#960;/6&#215;L&#215;W&#215;H (L=length of the longest axis of the tumor, W=perpendicular width, H=perpendicular height).</li>
	<li>Tumors can be analyzed by histology (fix in 10% neutral buffered formalin), flow cytometry (create single cell suspensions), protein (prepare tissue lysate in RIPA buffer), or RNA (immediately place tissue in RNAlater).</li>
	<li>For immunological analysis, also collect the prostate tumor-draining para-aortic lymph nodes (Figure 1B, orange) and the spleen. 
	NOTE: If following mice for survival, the endpoint of this model is defined as the appearance of hemorrhagic abdominal ascites36 and/or decreased ambulation, grooming, and/or piloerection37. Mice for survival analysis receive pre- and post-operative analgesia (protocol steps 2.2, 4.1) and must be monitored regularly. Mice should be separated into individual cages if any fighting occurs, and should be humanely euthanized upon the appearance of any of the above endpoint readouts.</li>
</ol>
7. Surgical Castration to Model CRPC
<ol>
	<li>To model CRPC, perform the above intra-prostatic injection protocol (protocol steps 1-5).</li>
	<li>At least one week later, after tumor development, perform surgical castration via cauterization, as previously described38.</li>
	<li>Monitor tumor regression and recurrence by bioluminescent imaging. After castration, tumor regression will occur within 3 days and tumor recurrence will occur within approximately 30 days, representing CRPC.</li>
</ol>

The authors have nothing to disclose.

In this manuscript we outline the protocol to perform surgical intra-prostatic cancer cell injections. We utilized the androgen-dependent and MYC-overexpressing (MYC overexpression is seen up to 80-90% of human prostate cancer39) murine prostate cancer cell line, Myc-CaP, originally isolated from the Hi-Myc mouse32,33. This cell line was stably transduced to express both luciferase and mCherry, for non-invasive in vivo bioluminescent and fluorescent tumor imaging, respectively. Further, surgical castration was also performed after androgen-dependent tumor development, leading to tumor regression and subsequent recurrence. Therefore, we provide details to model both orthotopic androgen-dependent prostate cancer and CRPC in an immunocompetent host.
Myc-CaP cells were injected into the anterior prostate lobe of mice. The mouse prostate consists of the anterior, ventral, and dorsolateral prostate lobes, and the human prostate consists of a peripheral zone, transitional zone, and central zone within a single lobe40. While prior studies have anatomically and histologically compared the dorsolateral mouse lobe to the human peripheral zone, the site of the majority of prostate cancers41, and the anterior mouse lobe to the human central zone42,43, more recent and comprehensive analysis has demonstrated that the anterior lobe and dorsolateral lobe display closely related gene expression patterns, as compared to the ventral lobe.44 Further, prostate cancer development has been observed in the anterior lobe of GEMs40, and, for the intra-prostatic procedure, the anterior lobe allows for the injection of the necessary volume of cancer cell solution with minimal leakage and variability.
Using s.c. and transgenic GEM cancer models have multiple flaws and limitations. S.c. tumors grown in an artificial TME have differential responses to chemotherapies, in contrast to both orthotopic tumors from the same cell lines and human disease20,21,22. This may be due to the altered vasculature of s.c. tumors, as exemplified by their differential response to anti-angiogenic therapy18,19. On the contrary, orthotopic tumors develop with a proper TME, draining lymph nodes, and vasculature, and can be performed with murine cell lines, thereby also allowing for analysis of tumor immunology and response to immunotherapies.
Transgenic GEMs develop tumors with a proper TME in an immunocompetent host, yet these models typically oversimplify human cancer by developing tumors with single or few genetic alterations29. An analysis of Myc-CaP and other prostate cancer cell lines revealed that they contained much greater somatic copy number alterations and chromosomal alterations than tumors from the Hi-Myc mice and other GEMs from which they were derived29. Further, GEMs are limited by the increased cost and time needed for mice breeding to perform experiments of sufficient power. Orthotopic tumor modeling can overcome these limitations. Human and murine prostate cancer cell lines contain many genetic alterations relevant to human disease29, and, like human cancer, also show great heterogeneity between individual cells30. Orthotopic murine syngeneic tumors allow for immunological analyses, while orthotopic human xenogeneic tumors allow for analyses of therapeutics on human cells. Finally, unlike with GEMs, cell lines can be modified before injection, allowing for expression of bioluminescent or fluorescent imaging molecules to monitor tumor growth, normalize tumor burden among experimental groups, monitor response to treatment, and to follow tumor regression and CRPC recurrence after surgical castration.
Critical steps in this protocol include locating and externalizing the seminal vesicle and attached anterior prostate lobe without damaging other tissues or puncturing the seminal vesicle, performing a successful intra-prostatic injection of the 30 &#181;L of cell suspension without leakage, and properly collecting any leakage to prevent non-orthotopic tumor development throughout the abdomen. The major limitation of intra-prostatic injections is attaining the technical skill required to minimize tumor variability between mice. This is especially important for modeling CRPC, which has the added variable of surgical castration. Intra-prostatically injected and castrated mice must also be followed closely for recovery and adverse events, as they have undergone two major survival surgeries. Another limitation is the time of each intra-prostatic injection. This can be reduced to as low as 20 min, and the surgeon assistant can prepare the next mouse as the current mouse is being sutured. Finally, orthotopic Myc-CaP tumors are aggressive, fast growing tumors that reach the survival endpoint in approximately 46 days (and as early as 35 days) due to the primary tumor mass. Studies requiring slower tumor development or long-term treatments should be optimized empirically for the initial injection cell count and treatment regimen. In contrast to the limitations of s.c. tumors and GEMs, all of the above limitations of the orthotopic tumor model can be overcome, and additional modifications of the protocol can be made based on individual experimental needs.
As the orthotopic tumor model involves the use of in vitro-handled cells, these cells can be modified depending on the needs of the study. Here, we modified these cells to stably express luciferase and mCherry for in vivo tumor monitoring. We have also performed a CRISPR-Cas9 knockout of the tumor suppressor PTEN, to generate a more aggressive, clinically relevant cell line that grows faster as orthotopic tumors (manuscript in review). With the advantages of the orthotopic tumor model, the ability to study both androgen-dependent prostate cancer and CRPC, and the potential to express imaging modalities or knockdown or overexpress select genes, this protocol serves as a valuable resource for all prostate cancer research.

Prostate cancer is estimated to have the highest incidence (161,360 men) and cause the third-most male cancer deaths (84,590 men) in 20171. Upon diagnosis, prostate tumors are androgen-dependent, and are treated by surgical prostatectomy, radiation therapy, and/or androgen deprivation therapy (ADT), yet each treatment is associated with multiple major morbidities and complications2,3,4,5,6,7,8,9,10. Despite tumor regression after ADT, nearly all tumors recur as castration-resistant prostate cancer (CRPC). At this stage, approved therapies include docetaxel, Sipuleucel-T immunotherapy, and the anti-androgen small molecules enzalutamide and abiraterone, yet no individual therapy confers a survival benefit of more than 5.2 months11,12,13,14,15,16,17. Therefore, men at all stages of prostate cancer need both improved treatment options and management of morbidities, for which optimal pre-clinical disease modeling is crucial.
With correct procedure, prostate cancer cell lines can be surgically instilled into the murine prostate, leading to the development of both syngeneic or xenogeneic orthotopic tumors. Orthotopic tumor modeling is ideal for all tumor biology and drug development research, allowing for tumor development with a clinically representative tumor microenvironment (TME). Prior studies have demonstrated that subcutaneous (s.c.) tumors have an altered tumor vasculature, leading to differential and less clinically accurate responses to anti-angiogenic therapies18,19. In addition, multiple studies have observed increased or decreased efficacy of multiple chemotherapeutics in treating the same cell line, depending on whether it was administered s.c. or orthotopically, the latter of which best represented what is seen in human cancer20,21,22. Further, only in an orthotopic model of colon cancer, but not in the s.c. model, did tumors produce the correct degradative enzymes necessary to induce metastasis23. Finally, as immunotherapies continue to emerge at the forefront of cancer therapy, and especially as they have yet to provide significant benefit for prostate cancer24,25, syngeneic pre-clinical models with accurate TME and draining lymph nodes in immunocompetent hosts are critical.
There are many factors responsible for these inconsistent findings based on tumor site. With a different TME, cancer cells are exposed to different tissue-specific endothelium and altered angiogenesis, thereby affecting tumor development26,27. Orthotopic tumors with the correct TME allow for clinically relevant drug delivery, hypoxic conditions, and evaluation of anti-angiogenic therapies28. While genetically engineered models (GEMs) do contain an accurate TME, they require long times for breeding, high cost, and are often based on manipulations of single or few genes knocked out or overexpressed beyond clinically relevant levels. In contrast, the human or murine prostate cancer cell lines used in orthotopic tumors, like human tumors, are much more genetically complex both within single cells and in displaying heterogeneity between cells29,30. Also unlike GEMs, orthotopic cancer cell lines can be engineered to express imaging modalities or increased or decreased levels of other molecules of interest, and in vitro and in vivo experimental results can be directly compared. Orthotopic tumors can also be formed from primary patient-derived cells. Here, we report the methodology for performing intra-prostatic injections of prostate cancer cells that form orthotopic androgen-dependent tumors, and, after castration, recur as orthotopic CRPC.

<table><tbody><tr><td>Myc-CaP cell line</td><td>ATCC</td><td>CRL-3255</td><td>Verify as mycoplasma-free before use</td></tr><tr><td>Micro-dissecting scissors</td><td>Roboz</td><td>RS-5910</td><td></td></tr><tr><td>Graege forceps</td><td>Roboz</td><td>RS-5135</td><td></td></tr><tr><td>Graefe tissue forceps</td><td>Roboz</td><td>RS-5150</td><td></td></tr><tr><td>Olsen-Hegar needle holder with suture cutters</td><td>FST</td><td>12002-12</td><td></td></tr><tr><td>50 &amp;micro;L Syringe 705 RN SYR</td><td>Hamilton</td><td>7637-01</td><td>Sterilize by ethylene oxide gas</td></tr><tr><td>28-gauge Needles Small Hub RN</td><td>Hamilton</td><td>7803-02</td><td>Point style 4, Angle 45&amp;deg;, Length 0.75 in. Sterilized by ethylene oxide gas</td></tr><tr><td>RPMI</td><td>Gibco</td><td>18875-093</td><td></td></tr><tr><td>FBS</td><td>Gibco</td><td>10437-028</td><td></td></tr><tr><td>Pencillin/Streptomycin</td><td>Gibco</td><td>15140-122</td><td></td></tr><tr><td>PBS</td><td>Gibco</td><td>14190-144</td><td></td></tr><tr><td>0.25% trypsin-EDTA</td><td>Gibco</td><td>25200-056</td><td></td></tr><tr><td>Matrigel basement membrane matrix, phenol red-free, LDEV-free</td><td>Corning</td><td>356237</td><td>Thaw on ice in 4&amp;deg;C overnight before use</td></tr><tr><td>Isoflurane</td><td>Henry Schein</td><td>11695-0500-2</td><td>Acquired from Northwestern University Center for Comparative Medicine (CCM)</td></tr><tr><td>26 5/8-gauge syringe</td><td>BD</td><td>309597</td><td>For meloxicam and buprenorphine injections</td></tr><tr><td>Buprenorphine hyrochloride 0.3 mg/mL</td><td></td><td>12496-0757-5</td><td>Controlled substance, acquired from Northwestern University CCM</td></tr><tr><td>Ophthalmic ointment lubrication</td><td>Akron</td><td>17478-162-35</td><td></td></tr><tr><td>Betadine surgical scrub (povidone-iodine, 7.5%)</td><td>Purdue Products</td><td>67618-151-16</td><td></td></tr><tr><td>Sterile non-adhering pads</td><td>Moore Medical</td><td>10775</td><td></td></tr><tr><td>Sterile alcohol wipes</td><td>Fisher Scientific</td><td>22-363-750</td><td></td></tr><tr><td>Surgical microscope Stemi DV4</td><td>Zeiss</td><td></td><td></td></tr><tr><td>Sterile polyester tipped applicators</td><td>Puritan</td><td>25-806 1PD</td><td></td></tr><tr><td>5-0 vicryl absorbable reverse cutting needle sutures</td><td>eSutures</td><td>J493G</td><td></td></tr><tr><td>4-0 nylon monfilament non-absorbable reverse cutting needle sutures</td><td>eSutures</td><td>699H</td><td></td></tr><tr><td>Glass bead sterilizer</td><td>Fine Science Tools</td><td>18000-45</td><td></td></tr><tr><td>Sterile saline 0.9% sodium chloride</td><td>Hospira</td><td>0409-4888-02</td><td></td></tr><tr><td>Meloxicam (Eloxiject) 5 mg/mL</td><td>Henry Schein</td><td>11695-6925-1</td><td>Acquired from Northwestern University CCM</td></tr><tr><td>D-luciferin Firefly, sodium salt monohydrate</td><td>Goldbio</td><td>LUCNA</td><td></td></tr><tr><td>IVIS Spectrum Imaging System</td><td>PerkinElmer</td><td></td><td></td></tr><tr><td>Cauery surgical pen</td><td>Bovie Medical Corporation</td><td>AA01</td><td></td></tr><tr><td>CD3&amp;epsilon; antibody (clone 2GV6)</td><td>Ventana</td><td>790-4341</td><td></td></tr><tr><td>Caliper</td><td>Fisher Scientific</td><td>14-648-17</td><td></td></tr><tr><td>Androgen receptor antibody</td><td>Thermo Scientific</td><td>RB-9030-P1</td><td>1:500 staining dilution</td></tr><tr><td>Synaptophysin antibody (clone Z66)</td><td>Life Technologies</td><td>18-0130</td><td>1:200 staining dilution</td></tr></tbody></table>

a bioluminescent and fluorescent orthotopic syngeneic murine model of androgen-dependent and castration-resistant prostate cancer

Orthotopic tumor modeling is a valuable tool for pre-clinical prostate cancer research, as it has multiple advantages over both subcutaneous and transgenic genetically engineered mouse models. Unlike subcutaneous tumors, orthotopic tumors contain more clinically accurate vasculature, tumor microenvironment, and responses to multiple therapies. In contrast to genetically engineered mouse models, orthotopic models can be performed with lower cost and in less time, involve the use of highly complex and heterogeneous mouse or human cancer cell lines, rather that single genetic alterations, and these cell lines can be genetically modified, such as to express imaging agents. Here, we present a protocol to surgically injecting a luciferase- and mCherry-expressing murine prostate cancer cell line into the anterior prostate lobe of mice. These mice developed orthotopic tumors that were non-invasively monitored in vivo and further analyzed for tumor volume, weight, mouse survival, and immune infiltration. Further, orthotopic tumor-bearing mice were surgically castrated, leading to immediate tumor regression and subsequent recurrence, representing castration-resistant prostate cancer. Although technical skill is required to carry out this procedure, this syngeneic orthotopic model of both androgen-dependent and castration-resistant prostate cancer is of great use to all investigators in the field.

In this manuscript, we surgically injected the murine prostate cancer cell line, Myc-CaP, into the anterior prostate lobe (Figure 1A), leading to the development of orthotopic prostate tumors with a clinically relevant TME and the correct prostate-draining lymph nodes (Figure 1B). This was performed using micro-dissecting scissors, Graefe forceps, Graefe tissue forceps, a needle holder with suture cutters, and a 50 &#181;L syringe with a 28-gauge needle (Figure 1C). After performing an approximately 1 cm midline abdominal incision above the preputial glands (Figure 1D), one seminal vesicle and attached anterior prostate lobe were located and externalized (Figure 1E) and 30 &#181;L (1x106 cells) of a 1:1 PBS/matrigel cell suspension was injected into the prostate (Figure 1F), as initially verified by the engorgement of the lobe and the lack of leakage (Figure 1G).
To monitor the orthotopic tumor growth, we stably transfected Myc-CaP cells to express both firefly luciferase and mCherry, allowing for tumors to be followed by non-invasive in vivo bioluminescence (Figure 2A) and fluorescence (Figure 2B), respectively. One limitation of this imaging is that, depending on the strength of the signal, imaging quantification may saturate while the tumor continues to increase in size. Therefore, with high signal intensities, this in vivo imaging is more useful for initially normalizing tumor burden across experimental groups and for later determining decreases in tumor size after experimental treatments. Additional imaging modalities can also be utilized, such as small animal MRI, PET, or CT.
Orthotopic tumors were dissected from the abdomen on day 30 after intra-prostatic injection (Figure 3A). Orthotopic tumors should be located at the site of the anterior prostate lobe. Tumor masses throughout the abdomen or attached to the anterior abdominal wall indicate improper intra-prostatic injection and leakage. With proper technique, tumor volume (Figure 3B) and weight (Figure 3C) can be recorded with relatively small standard error. However, as observed, there will be some variability with small and large tumor masses. Therefore, initial use of pre-treatment imaging quantification to equalize tumor burden between experimental arms is critical for all experiments. Further, as these murine cancer cells were injected into immunocompetent FVB/NJ mice, the TME can be analyzed by immunohistochemistry (IHC) (or flow cytometry or other techniques) for CD3 T cells (Figure 3D) (or other immune cell types). Finally, this model provides an objective survival endpoint, as the large primary tumor mass causes hemorrhagic abdominal ascites36 (Figure 3E) and/or decreased ambulation, grooming, and/or piloerection37. Occasionally, death may also be caused by tumor growth blocking urine output.
Finally, this model can be utilized to study both androgen-dependent prostate cancer and CRPC, the latter of which confers poor prognosis and is in need of novel treatment options. After orthotopic tumor development, mice were surgically castrated, as previously described38. As this is the second major survival surgery, extra care must be given to monitor for recovery and any adverse events or complications. Within 3 days after castration, strong tumor regression was observed, followed by subsequent tumor recurrence after approximately 30 days, representing CRPC (Figure 4A). CRPC tumors can be dissection and analyzed histologically, and do not display any neuroendocrine differentiation, as they maintain high AR levels and are negative for the neuroendocrine marker, synaptophysin (Figure 4B).
<img alt="Figure 1" class="xfigimg" src="/files/ftp_upload/57301/57301fig1.jpg" /> 
Figure 1: Anterior prostate lobe, draining lymph nodes, and representative technique for intra-prostatic cell injections. Images of the (A) right anterior prostate lobe (black, *), attached right seminal vesicle (white), right testicle and fat pad (green), and bladder (yellow), (B) bilateral prostate-draining para-aortic lymph nodes (orange), (C) micro-dissecting scissors, Graefe forceps, Graefe tissue forceps, an needle holder with suture cutters, and 50 &#181;L syringe with 28-gauge needle (left to right), (D) midline incisions, (E) seminal vesicle and anterior prostate lobe externalization, (F), intra-prostatic injection, and (G) engorgement of the anterior prostate lobe. <a href="https://cloudflare-jove-com.remotexs.ntu.edu.sg/files/ftp_upload/57301/57301fig1large.jpg" target="_blank">Please click here to view a larger version of this figure.</a>
<img alt="Figure 2" class="xfigimg" src="/files/ftp_upload/57301/57301fig2.jpg" /> 
Figure 2: In vivo bioluminescent and fluorescent tumor imaging. (A) Luciferase- and (B) mCherry-expressing orthotopic Myc-CaP tumors were imaged using an IVIS Spectrum Imaging System. Bioluminescence was quantified by total flux (photons/s). <a href="https://cloudflare-jove-com.remotexs.ntu.edu.sg/files/ftp_upload/57301/57301fig2large.jpg" target="_blank">Please click here to view a larger version of this figure.</a>
<img alt="Figure 3" class="xfigimg" src="/files/ftp_upload/57301/57301fig3.jpg" /> 
Figure 3: Orthotopic tumor analyses by tumor volume, weight, histology for immune infiltration, and survival. Orthotopic tumors were dissected on day 30 after intra-prostatic injection and analyzed by (A) gross imaging, (B) tumor volume (&#960;/6&#215;L&#215;W&#215;H; L=length of the longest axis of the tumor, W=perpendicular width, H=perpendicular height), (C) tumor weight, (D) CD3 IHC (scale bar=100 &#181;m), and (E) survival, with the objective endpoint as the appearance of hemorrhagic abdominal ascites. (A-B) Data represented as mean &#177; standard error of the mean. <a href="https://cloudflare-jove-com.remotexs.ntu.edu.sg/files/ftp_upload/57301/57301fig3large.jpg" target="_blank">Please click here to view a larger version of this figure.</a>
<img alt="Figure 4" class="xfigimg" src="/files/ftp_upload/57301/57301fig4.jpg" /> 
Figure 4: Intra-prostatic injections with subsequent surgical castration to model both androgen-dependent prostate cancer and CRPC. (A) Mice bearing orthotopic luciferase-expressing tumors were imaged by bioluminescence pre- and post-castration (Cx), and (B) recurred CRPC tumors were dissected (black=orthotopic prostate tumor; yellow=bladder) and analyzed by H&#38;E, AR IHC, and synaptophysin IHC (with positive murine control) (scale bar=50 &#181;m). <a href="https://cloudflare-jove-com.remotexs.ntu.edu.sg/files/ftp_upload/57301/57301fig4large.jpg" target="_blank">Please click here to view a larger version of this figure.</a>

Watch this Scientific Journal Video about A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer at JoVE.com

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

The goal of this protocol is to demonstrate the intra-prostatic injection of prostate cancer cells, with subsequent castration. Orthotopic pre-clinical models of androgen-dependent and castration-resistant prostate cancer are critical to study the disease in the context of a clinically relevant tumor microenvironment and an immunocompetent host.

Orthotopic tumor modeling is a valuable tool for pre-clinical prostate cancer research, as it has multiple advantages over both subcutaneous and ...

a-bioluminescent-fluorescent-orthotopic-syngeneic-murine-model

Nanyang Technological University

Research

JoVE Journal

Cancer Research

12.9K Views.  Northwestern University Feinberg School of Medicine. Het doel van dit protocol is om aan te tonen van de intra-prostaat injectie van prostaat kankercellen, met latere castratie. Orthotopic preklinische modellen van androgeen-afhankelijke en castratie-resistente prostaatkanker zijn cruciaal voor het bestuderen van de ziekte in het kader van een klinisch relevante tumor communicatie en een immunocompetent host.

Video: A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

A Murine Orthotopic Bladder Tumor Model and Tumor Detection System

This protocol describes the generation of bladder tumors in female C57BL/6J mice using the murine bladder cancer cell line MB49, which has been modified to secrete human Prostate Specific Antigen (PSA), and the procedure for the confirmation of tumor implantation. In brief, mice are anesthetized using injectable drugs and are made to lay in the dorsal position. Urine is vacated from the bladder and 50 &#181;L of poly-L-lysine (PLL) is slowly instilled at a rate of 10 &#181;L/20 s using a 24 G IV catheter. It is left in the bladder for 20 min by stoppering the catheter. The catheter is removed and PLL is vacated by gentle pressure on the bladder. This is followed by instillation of the murine bladder cancer cell line (1 x 105 cells/50 &#181;L) at a rate of 10 &#181;L/20 s. The catheter is stoppered to prevent premature evacuation. After 1 h, the mice are revived with a reversal drug, and the bladder is vacated. The slow instillation rate is important, as it reduces vesico-ureteral reflux, which can cause tumors to occur in the upper urinary tract and in the kidneys. The cell line should be well re-suspended to reduce clumping of cells, as this can lead to uneven tumor sizes after implantation.
This technique induces tumors with high efficiency. Tumor growth is monitored by urinary PSA secretion. PSA marker monitoring is more reliable than ultrasound or fluorescence imaging for the detection of the presence of tumors in the bladder. Tumors in mice generally reach a maximum size that negatively impacts health by about 3 - 4 weeks if left untreated. By monitoring tumor growth, it is possible to differentiate mice that were cured from those that were not successfully implanted with tumors. With only end-point analysis, the latter may be mistakenly assumed to have been cured by therapy.

This protocol describes the generation of murine orthotopic bladder tumors in female C57BL/6J mice and the monitoring of tumor growth.

This protocol describes the generation of bladder tumors in female C57BL/6J mice using the murine bladder cancer cell line MB49, which has been modified ...

Virus Delivery of CRISPR Guides to the Murine Prostate for Gene Alteration

With an increasing incidence of prostate cancer, identification of new tumor drivers or modulators is crucial. Genetically engineered mouse models (GEMM) for prostate cancer are hampered by tumor heterogeneity and its complex microevolution dynamics. Traditional prostate cancer mouse models include, amongst others, germline and conditional knockouts, transgenic expression of oncogenes, and xenograft models. Generation of de novo mutations in these models is complex, time-consuming, and costly. In addition, most of traditional models target the majority of the prostate epithelium, whereas human prostate cancer is well known to evolve as an isolated event in only a small subset of cells. Valuable models need to simulate not only prostate cancer initiation, but also progression to advanced disease.
Here we describe a method to target a few cells in the prostate epithelium by transducing cells by viral particles. The delivery of an engineered virus to the murine prostate allows alteration of gene expression in the prostate epithelia. Virus type and quantity will hereby define the number of targeted cells for gene alteration by transducing a few cells for cancer initiation and many cells for gene therapy. Through surgery-based injection in the anterior lobe, distal from the urinary track, the tumor in this model can expand without impairing the urinary function of the animal. Furthermore, by targeting only a subset of prostate epithelial cells the technique enables clonal expansion of the tumor, and therefore mimics human tumor initiation, progression, as well as invasion through the basal membrane.
This novel technique provides a powerful prostate cancer model with improved physiological relevance. Animal suffering is limited, and since no additional breeding is required, overall animal count is reduced. At the same time, analysis of new candidate genes and pathways is accelerated, which in turn is more cost efficient.

This protocol describes a newly established method for virus delivery to the murine prostate. Using either CRISPR/Cas9 technology, gene overexpression, or Cre recombinase delivery, the technique allows orthotopic alteration of gene expression and implements a novel mouse model for prostate cancer.

With an increasing incidence of prostate cancer, identification of new tumor drivers or modulators is crucial. Genetically engineered mouse models (GEMM) ...

Generation of Tumor Organoids from Genetically Engineered Mouse Models of Prostate Cancer

Methods based on homologous recombination to modify genes have significantly furthered biological research. Genetically engineered mouse models (GEMMs) are a rigorous method for studying mammalian development and disease. Our laboratory has developed several GEMMs of prostate cancer (PCa) that lack expression of one or multiple tumor suppressor genes using the site-specific Cre-loxP recombinase system and a prostate-specific promoter. In this article, we describe our method for necropsy of these PCa GEMMs, primarily focusing on dissection of mouse prostate tumors. New methods developed over the last decade have facilitated the culture of epithelial-derived cells to model organ systems in vitro in three dimensions. We also detail a 3D cell culture method to generate tumor organoids from mouse PCa GEMMs. Pre-clinical cancer research has been dominated by 2D cell culture and cell line-derived or patient-derived xenograft models. These methods lack tumor microenvironment, a limitation of using these techniques in pre-clinical studies. GEMMs are more physiologically-relevant for understanding tumorigenesis and cancer progression. Tumor organoid culture is an in vitro model system that recapitulates tumor architecture and cell lineage characteristics. In addition, 3D cell culture methods allow for growth of normal cells for comparison to tumor cell cultures, rarely possible using 2D cell culture techniques. In combination, use of GEMMs and 3D cell culture in pre-clinical studies has the potential to improve our understanding of cancer biology.&#160;

We show a method for necropsy and dissection of mouse prostate cancer models, focusing on prostate tumor dissection. A step-by-step protocol for generation of mouse prostate tumor organoids is also presented.

Methods based on homologous recombination to modify genes have significantly furthered biological research. Genetically engineered mouse models (GEMMs) ...

Genetics

Using the Chicken Chorioallantoic Membrane In Vivo Model to Study Gynecological and Urological Cancers

Mouse models are the benchmark tests for in vivo cancer studies. However, cost, time, and ethical considerations have led to calls for alternative in vivo cancer models. The chicken chorioallantoic membrane (CAM) model provides an inexpensive, rapid alternative that permits direct visualization of tumor development and is suitable for in vivo imaging. As such, we sought to develop an optimized protocol for engrafting gynecological and urological tumors into this model, which we present here. Approximately 7 days postfertilization, the air cell is moved to the vascularized side of the egg, where an opening is created in the shell. Tumors from murine and human cell lines and primary tissues can then be engrafted. These are typically seeded in a mixture of extracellular matrix and medium to avoid cellular dispersal and provide nutrient support until the cells recruit a vascular supply. Tumors may then grow for up to an additional 14 days prior to the eggs hatching. By implanting cells stably transduced with firefly luciferase, bioluminescence imaging can be used for the sensitive detection of tumor growth on the membrane and cancer cell spread throughout the embryo. This model can potentially be used to study tumorigenicity, invasion, metastasis, and therapeutic effectiveness. The chicken CAM model requires significantly less time and financial resources compared to traditional murine models. Because the eggs are immunocompromised and immune tolerant, tissues from any organism can potentially be implanted without costly transgenic animals (e.g., mice) required for implantation of human tissues. However, many of the advantages of this model could potentially also be limitations, including the short tumor generation time and immunocompromised/immune tolerant status. Additionally, although all tumor types presented here engraft in the chicken chorioallantoic membrane model, they do so with varying degrees of tumor growth.

We present the chicken chorioallantoic membrane model as an alternative, transplantable, in vivo model for the engraftment of gynecological and urological cancer cell lines and patient-derived tumors.

Mouse models are the benchmark tests for in vivo cancer studies. However, cost, time, and ethical considerations have led to calls for alternative in vivo ...

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Tumor extracellular matrix has abundance of cancer related proteins that can be used as biomarkers for cancer molecular imaging. In this work, we demonstrated effective MR cancer molecular imaging with a small molecular peptide targeted Gd-DOTA monoamide complex as a targeted MRI contrast agent specific to clotted plasma proteins in tumor stroma. We performed the experiment of evaluating the effectiveness of the agent for non-invasive detection of prostate tumor with MRI in a mouse orthotopic PC-3 prostate cancer model. The targeted contrast agent was effective to produce significant tumor contrast enhancement at a low dose of 0.03 mmol Gd/kg. The peptide targeted MRI contrast agent is promising for MR molecular imaging of prostate tumor.

To demonstrate MR cancer molecular imaging with a small peptide targeted MRI contrast agent specific to clotted plasma proteins in tumor stroma in a mouse prostate cancer model.

Tumor extracellular  matrix has abundance of cancer related proteins that can be used as biomarkers  for cancer molecular imaging. In this work,  we ...

Medicine

An Orthotopic Murine Model of Human Prostate Cancer Metastasis

Our laboratory has developed a novel orthotopic implantation model of human prostate cancer (PCa). As PCa death is not due to the primary tumor, but rather the formation of distinct metastasis, the ability to effectively model this progression pre-clinically is of high value. In this model, cells are directly implanted into the ventral lobe of the prostate in Balb/c athymic mice, and allowed to progress for 4-6 weeks. At experiment termination, several distinct endpoints can be measured, such as size and molecular characterization of the primary tumor, the presence and quantification of circulating tumor cells in the blood and bone marrow, and formation of metastasis to the lung. In addition to a variety of endpoints, this model provides a picture of a cells ability to invade and escape the primary organ, enter and survive in the circulatory system, and implant and grow in a secondary site. This model has been used effectively to measure metastatic response to both changes in protein expression as well as to response to small molecule therapeutics, in a short turnaround time.

This orthotopic model of human prostate cancer allows for quantification of tumor size, circulating tumor cells, and formation of distinct metastasis to the lung. As cells must escape the primary organ, enter the blood stream, and implant into a secondary site, this model effectively recapitulates the scenario in humans.

Our laboratory has developed a novel orthotopic implantation model of  human prostate cancer (PCa). As PCa death is not due to the primary tumor, but  ...

Intra-Cardiac Injection of Human Prostate Cancer Cells to Create a Bone Metastasis Xenograft Mouse Model

As the most common male malignancy, prostate cancer (PC) ranks second in mortality, primarily due to a 65%-75% bone metastasis rate. Therefore, it is essential to understand the process and related mechanisms of prostate cancer bone metastasis for developing new therapeutics. For this, an animal model of bone metastasis is an essential tool. Here, we report detailed procedures to generate a bone metastasis mouse model via intra-cardiac injection of prostate cancer cells. A bioluminescence imaging system can determine whether prostate cancer cells have been accurately injected into the heart and monitor cancer cell metastasis since it has great advantages in monitoring metastatic lesion development. This model replicates the natural development of disseminated cancer cells to form micro-metastases in the bone and imitates the pathological process of prostate cancer bone metastasis. It provides an effective tool for further exploration of the molecular mechanisms and the in vivo therapeutic effects of this disease.

Here, we present a protocol for the intra-cardiac injection of human prostate cancer cells to generate a mouse model with bone metastasis lesions.

As the most common male malignancy, prostate cancer (PC) ranks second in mortality, primarily due to a 65%-75% bone metastasis rate. Therefore, it is ...

Murine Prostate Micro-dissection and Surgical Castration

Mouse models are used extensively to study prostate cancer and other diseases. The mouse is an excellent model with which to study the prostate and has been used as a surrogate for discoveries in human prostate development and disease. Prostate micro-dissection allows consistent study of lobe-specific prostate anatomy, histology, and cellular characteristics in the absence of contamination of other tissues. Testosterone affects prostate development and disease. Androgen deprivation therapy is a common treatment for prostate cancer patients, but many prostate tumors become castration-resistant. Surgical castration of mouse models allows for the study of castration resistance and other facets of hormonal biology on the prostate. This procedure can be coupled with testosterone reintroduction, or hormonal regeneration of the prostate, a powerful method to study stem cell lineages in the prostate. Together, prostate micro-dissection and surgical castration opens up a multitude of opportunities for robust and consistent research of prostate development and disease. This manuscript describes the protocols for prostate micro-dissection and surgical castration in the laboratory mouse.

This manuscript describes the protocols for prostate micro-dissection and surgical castration in the laboratory mouse. We also depict representative results produced by these protocols. Finally, we discuss the advantages and utilization of these protocols.

Mouse models are used extensively to study prostate cancer and other diseases. The mouse is an excellent model with which to study the prostate and has ...

Pre-clinical Orthotopic Murine Model of Human Prostate Cancer

To study the multifaceted biology of prostate cancer, pre-clinical in vivo models offer a range of options to uncover critical biological information about this disease. The human orthotopic prostate cancer xenograft mouse model provides a useful alternative approach for understanding the specific interactions between genetically and molecularly altered tumor cells, their organ microenvironment, and for evaluation of efficacy of therapeutic regimens. This is a well characterized model designed to study the molecular events of primary tumor development and it recapitulates the early events in the metastatic cascade prior to embolism and entry of tumor cells into the circulation. Thus it allows elucidation of molecular mechanisms underlying the initial phase of metastatic disease. In addition, this model can annotate drug targets of clinical relevance and is a valuable tool to study prostate cancer progression. In this manuscript we describe a detailed procedure to establish a human orthotopic prostate cancer xenograft mouse model.

Prostate cancer is the second most common cause of cancer-related deaths in the United States. An orthotopic cancer model provides a useful approach to understand the biology of prostate cancer and to evaluate the efficacy of therapeutic regimens. This protocol describes detailed steps necessary to establish an orthotopic prostate cancer mouse model.

To study the multifaceted biology of prostate cancer, pre-clinical in vivo models offer a range of options to uncover critical biological information ...

Generating a Murine Orthotopic Metastatic Breast Cancer Model and Performing Murine Radical Mastectomy

In vivo mouse models to assess breast cancer progression are essential for cancer research, including preclinical drug developments. However, the majority of the practical and technical details are commonly omitted in published manuscripts which, therefore, makes it challenging to reproduce the models, particularly when it involves surgical techniques. Bioluminescence technology allows for the evaluation of small amounts of cancer cells even when a tumor is not palpable. Utilizing luciferase-expressing cancer cells, we establish a breast cancer orthotopic inoculation technique with a high tumorigenesis rate. Lung metastasis is assessed utilizing an ex vivo technique. We, then, establish a mastectomy model with a low local recurrence rate to assess the metastatic tumor burden. Herein, we describe, in detail, the surgical techniques of orthotopic implantation and mastectomy for breast cancer with a high tumorigenesis rate and low local recurrence rates, respectively, to improve breast cancer model efficiency.

We introduce a murine orthotopic breast cancer model and radical mastectomy model with bioluminescence technology to quantify the tumor burden to mimic human breast cancer progression.

In vivo mouse models to assess breast cancer progression are essential for cancer research, including preclinical drug developments. However, the majority ...

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Samenvatting

Meer video's verkennen

Hoofdstukken in deze video